Kazia Therapeutics Limited(KZIA)Earnings, Financials & Key Ratios
KZIA•NASDAQ
$13.10
Price updated Jul 7, 2026
AboutKazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Show more
- Revenue$42K-98.2%
- EBITDA-$13M+50.1%
- Net Income-$21M+22.7%
- EPS (Diluted)-18.90+65.6%
- Gross Margin100%
- EBITDA Margin-31626.19%-2644.8%
- Operating Margin-33850%-2644.9%
- Net Margin-49290.48%-4148.4%
KZIA Price & Volume
Kazia Therapeutics Limited (KZIA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Solvency
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent clinical funding shortfall
Key Thesis Takeaways
- Kazia Therapeutics operates as a high-risk, pre-commercial biotechnology entity characterized by a total absence of sustainable revenue and a reliance on external capital to fund its oncology research.
- The company faces severe financial distress, evidenced by a negative equity position of $8.3 million as of 2025Q4 and a critical current ratio of 0.35.
- Investors should remain cautious as the firm's inability to generate operating leverage, combined with a $13.3 million quarterly operating loss in 2026Q2, suggests that significant dilution or liquidity events are likely required to maintain operations.
Verdict Logic
the company's precarious liquidity position, evidenced by a current ratio of 0.35 and a negative equity base of $8.3 million, suggests an imminent risk of insolvency or severe shareholder dilution.
KZIA Growth Metrics
Kazia Therapeutics Limited (KZIA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.23%
5 Years-46.83%
3 Years61.34%
TTM250944.28%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM61.7%
Return on Capital
10 Years-82.87%
5 Years-132.34%
3 Years-223.1%
Last Year-
Peers Comparison
Key metrics vs top competitors for Kazia Therapeutics Limited (KZIA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.10 | $21.22M | -1.00 | -98.18% | -49290.48% | — | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $23.24 | $2.05B | -7.06 | 627.84% | -112.01% | -256.66% | — | |
| $44.01 | $2.62B | -6.18 | 48.03% | -639.84% | -34.11% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — |
Compare KZIA vs Peers
Kazia Therapeutics Limited (KZIA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when KZIA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KZIA Frequently Asked Questions
Kazia Therapeutics Limited (KZIA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Kazia Therapeutics Limited's revenue?
Kazia Therapeutics Limited (KZIA) reported $2.5M in revenue for fiscal year 2025. This represents a 87% decrease from $19.3M in 1999.
How fast is Kazia Therapeutics Limited growing?
Kazia Therapeutics Limited (KZIA) saw revenue decline by 98.2% over the past year.
Is KZIA profitable?
Kazia Therapeutics Limited (KZIA) reported a net loss of $50.7M for fiscal year 2025.
Dividend & Returns
What is Kazia Therapeutics Limited's free cash flow?
Kazia Therapeutics Limited (KZIA) had negative free cash flow of $16.5M in fiscal year 2025, likely due to heavy capital investments.